PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Diabetes & Metabolism Journal10.4093/dmj.2012.36.4.2622012364262GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver DiseaseJinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Won-Young Leehttps://synapse.koreamed.org/DOIx.php?id=10.4093/dmj.2012.36.4.262, https://synapse.koreamed.org/pdf/10.4093/dmj.2012.36.4.262, http://e-dmj.org/upload/pdf/dmj-36-262.pdf
Journal of Hepatology10.1016/s0168-8278(20)30765-0202073S124HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trialManal Abdelmalek, Jaeduk Choi, Youngmin Kim, Kyounghee Seo, Marcus Hompesch, Seungjae Baekhttps://api.elsevier.com/content/article/PII:S0168827820307650?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827820307650?httpAccept=text/plain
Journal of Gastroenterology and Hepatology10.1046/j.1440-1746.17.s1.10.x200217S186-S190Non-alcoholic fatty liver diseasePAUL ANGULO, KEITH D LINDORhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1440-1746.17.s1.10.x, https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1440-1746.17.s1.10.x, http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1440-1746.17.s1.10.x/fullpdf
Archives of Hepatitis Research10.17352/ahr.000014201731029-036Farnesoid X Receptor Agonist as a new treatment option for Non-Alcoholic Fatty Liver disease: A ReviewS Singh, KK Kharbandahttps://www.peertechzpublications.com/articles/AHR-3-114.pdf
Journal of Gastroenterology and Hepatology10.1046/j.1440-1746.17.s3.32.x200217S385-S388Treatment of non-alcoholic fatty liver diseaseARUN J SANYALhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1440-1746.17.s3.32.x, https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1440-1746.17.s3.32.x, http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1440-1746.17.s3.32.x/fullpdf
Journal of Diabetes10.1111/j.1753-0407.2012.00204.x201243266-280Non-alcoholic fatty liver diseaseAna C. TUYAMA, Charissa Y. CHANGhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1753-0407.2012.00204.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1753-0407.2012.00204.x/fullpdf
Alimentary Pharmacology & Therapeutics10.1046/j.1365-2036.2003.01493.x2003178977-986Non-alcoholic fatty liver diseaseL. M. Alba, K. Lindorhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2036.2003.01493.x, https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2036.2003.01493.x, http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2036.2003.01493.x/fullpdf
Hepatology Research10.1111/j.1872-034x.2011.00867.x20114110911-920Clinicopathological features of non-alcoholic fatty liver diseaseKazushi Sugimoto, Yoshiyuki Takeihttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1872-034X.2011.00867.x
Journal of Gastroenterology and Hepatology10.1111/jgh.1224220132879-80Treatment of non-alcoholic fatty liver diseaseYoshiyuki Takeihttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjgh.12242, https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjgh.12242, http://onlinelibrary.wiley.com/wol1/doi/10.1111/jgh.12242/fullpdf
Gastroenterology10.1016/s0016-5085(18)33839-320181546S-1159Su1498 - A Highly Selective and Potent Farnesoid X Receptor (FXR) Agonist EDP-305 Reduces Liver Steatosis, Ballooning, and Non-Alcoholic Fatty Liver Disease Activity (NAS) in two Murine Models of Non-Alcoholic Steatohepatitis (NASH)Li-Juan Jiang, Mary Chau, Yang Li, Yat Sun Orhttps://api.elsevier.com/content/article/PII:S0016508518338393?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508518338393?httpAccept=text/plain